UBS Group Forecasts Strong Price Appreciation for Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Stock

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) had its target price lifted by analysts at UBS Group from $21.00 to $22.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s price target indicates a potential upside of 21.48% from the stock’s current price.

Separately, William Blair raised shares of Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.

Telix Pharmaceuticals Limited American Depositary Shares Stock Performance

Shares of NASDAQ TLX opened at $18.11 on Monday. Telix Pharmaceuticals Limited American Depositary Shares has a 52 week low of $14.01 and a 52 week high of $19.99. The firm has a 50 day moving average price of $15.93.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.